Categories
Featured

A US supercomputer with 8,000 Intel Xeon CPUs and 300TB of RAM is being auctioned — 160th most powerful computer in the world has some maintenance issues though and will cost thousands per day to run

[ad_1]

The Cheyenne supercomputer, based at the NCAR-Wyoming Supercomputing Center (NWSC) in Cheyenne, Wyoming, was ranked as the 20th most powerful computer in the world in 2016 – but now it’s up for sale through the US General Services Administration (GSA).

By November 2023, the 5.34-petaflops system’s ranking had slipped to 160th in the world, but it’s still a monster, able to carry out 5.34 quadrillion calculations per second. It has been put to a number of noteworthy purposes in the past, including studying weather phenomena and predicting natural disasters.

[ad_2]

Source Article Link

Categories
Bisnis Industri

Apple cuts cost of 2024 MLS Season Pass by 30%

[ad_1]

2024 MLS Season Pass
Enjoy the rest of the MLS season at a sweet discount, starting now.
Photo: MLS

Soccer fans can watch the rest of the MLS season for $69. That’s $30 less than what Apple typically charges for an MLS Season Pass.

Subscribers can stream every match plus analysis and exclusive content. No Apple device required.

Get a discount on 2024 MLS Season Pass

Apple is the exclusive source for streaming Major League Soccer in over 100 countries. Its MLS Season Pass subscription has given fans access to the games since the start of the season in February with no blackouts.

Joining now means you’ve missed a few games, but it comes with a significant discount. The cost is down to $69, or $59 for Apple TV+ subscribers. That’s $30 less than the price at the start of the season, as noted.

And there’s plenty of soccer still to come. The Pass includes the rest of the season plus the entire playoffs and the League Cup.

Subscribe now from: Apple

Note that, unless it’s cancelled, the MLS Season Pass subscription automatically renews at the beginning of the 2025 season at the regular price.

Apple offers this sports streaming service but it it’s watchable from a wide variety of devices. Beyond iPhone, Mac and iPad, the Apple TV app is available on smart TVs, streaming devices, set-top boxes, and game consoles, as well as on the web at tv.apple.com.



[ad_2]

Source Article Link

Categories
Featured

Peacock may increase the cost of its monthly and annual plans again

[ad_1]

It looks like Peacock is raising prices again for the second time in less than a year. According to Variety, the monthly Premium with ads plan will “increase by $2 to $7.99”, officially making it more expensive than Netflix’s Standard with ads option. The platform’s Premium Plus (which the report points out is “mostly ad-free”) is seeing a similar hike as it’ll cost $13.99 a month. Variety states “Peacock’s Premium annual price” will soon become $79.99, “while Premium Plus is going from $119.99 to $139.99” for the year.

These changes apparently take effect at different times for different groups. For new customers, they’ll see the increase on July 18. Current subscribers won’t see the hike until or after August 17. It depends on “their next billing date”. 

[ad_2]

Source Article Link

Categories
Featured

The obscure little PC that wanted to be a big NAS — super compact Maiyunda M1 doesn’t cost that much, offers up to 40TB SSD storage, runs Windows and has 4 Gigabit Ethernet ports

[ad_1]

At first glance, the Maiyunda M1 doesn’t look all that special. It’s a mini PC with a large on/off button on the front, alongside a TF card slot, a USB 3.0 port, and two USB 2.0 ports. On the rear, there are HDMI 2.0 and DP ports to allow the device to drive two screens simultaneously (4K/60Hz). There are also four 2.5GbE RJ45 ports plus two additional USB 2.0 slots.

With dimensions of just 165 x 147.5 x 59mm, not including the 52mm leg pads, the M1 with its all-aluminum shell looks like any mini PC, and even its manufacturer describes it as “unassuming”.

[ad_2]

Source Article Link

Categories
Life Style

Africa’s postdoc workforce is on the rise — but at what cost?

[ad_1]

Conceptual illustration depicts African postdocs climbing

Illustration: Fabrizio Lenci

Lire en français sur Nature Africa

Johnblack Kabukye struggles to explain to his colleagues back home in Uganda why he’s doing a two-year stint as a postdoctoral researcher in Sweden. “If you say you’re doing a master’s or a PhD, it’s clear what that means,” says the digital-health specialist, who worked as a physician for a decade before switching to research. But a postdoc? “It’s not a thing that is understood,” he says.

The skills he’s learning at Stockholm University while building electronic health tools tailored to patients’ needs are certainly useful for his job as a physician and informatician at the Uganda Cancer Institute (UCI) in Kampala. But the postdoc format itself — a short-term position designed to bridge the gap between doctoral student and tenured academic — makes little sense in Uganda, where it is common to have a permanent teaching job at a university before even embarking on a PhD.

“I have not heard of a single postdoc opportunity in Uganda,” Kabukye says.

That could soon change across Africa. The number of people gaining PhDs in the continent is growing, and so is the need for postdoctoral employment. “There is definitely greater awareness of the postdoc position, and more and more postdocs,” says Gordon Awandare, pro-vice-chancellor in charge of academic and student affairs at the University of Ghana in Accra.

But as the continent’s postdoctoral employment needs have grown, so too have fears that the problems created by a proliferation of postdoc positions in other parts of the world — which critics say trap young researchers in a cycle of poorly paid, short-term positions with no job security — could also arise in African countries.

Breaking ground

Postdoc frustration is a recurring theme in studies that look at early-career researchers. Two global surveys of postdoctoral students by Nature, one published in 2020 and the other last year, found that more than one-third of respondents were dissatisfied with their lot. A lack of job security, career-advancement opportunities and funding were the most-cited reasons.

Nature’s surveys underscore the dearth of postdoctoral researchers in Africa. Of the 3,838 postdocs surveyed in June last year, only 91 were based on the continent. The number of respondents (who were self-selecting) were too few, and too geographically concentrated in three countries — South Africa, Nigeria and Egypt — to be viewed as representative of the continent. Yet, they offer tantalizing glimpses of an emerging segment of the global research workforce.

For example, African postdocs were older than the global average, with more than 40% aged 41 or older. They were also more likely to be doing their postdoc in their home country (68% in Africa compared with 39% globally) and they were much less likely, than the global average, to be employed on fixed-term fellowships or contracts (see ‘Employment matters’). Their pay also stands out: 60% said they earned less than US$15,000 per year — the lowest option survey-takers could tick, and a fraction of what most postdocs are paid in Europe and North America. Lower costs of living play some part in the lower salaries, but not enough to justify the gap (see ‘A continental shift’).

A CONTINENTAL SHIFT. Graphic compares age and pay of African postdocs – results taken from 2023 Nature survey.

Postdocs in Africa were also more likely to report having a second job alongside their postdoc than were other respondents, on average (33% of respondents in Africa, compared with 10% of respondents overall). The most common reason was to provide extra income (71%), while 57% said their second job gave their skills and career prospects a boost. However, notes Awandare, the tendency of many African postdocs to have permanent academic positions before becoming a postdoc could be a confounding factor in this measure.

Yet, and perhaps surprising given their low pay, Africa-based postdocs were the most optimistic about their futures of all respondents from the geographical regions represented. Overall, 64% of Africa-based respondents reported that they felt positive about their future job prospects, compared with 41% globally. Postdocs in Africa were twice as likely to say that their postdoc roles were better than they imagined (25% compared with 12% overall). And 42% of respondents in Africa felt that they had better prospects than previous generations of postdocs, far exceeding the 15% global average.

EMPLOYMENT MATTERS. Graphic shows results taken from 2023 Nature postdoc survey.

That optimism makes sense to Awandare, who thinks that postdocs in his country might feel more important than do their peers who work in large laboratories overseas. In addition to his leadership role at the University of Ghana, he founded and runs the West African Centre for Cell Biology of Infectious Pathogens at the university. He says postdocs at the centre are treated the same as faculty members. “In some advanced institutions, they wouldn’t get that recognition and status,” he notes.

And even though their salaries are low by international standards, postdocs at his centre can be better paid than entry-level permanent university staff who only teach, he says. This is because postdocs tend to be paid out of lucrative international grants. “Ten to fifteen years ago, many of these positions would have been overseas — but now funders, to their credit, increasingly provide positions on the continent,” he says.

A different set-up

Employment structures also differed between Africa and the rest of the world, according to Nature’s survey. Although similar proportions of postdocs were employed in academia in Africa as they were globally (around 90%), the proportion of part-time postdocs was higher in Africa — 12% compared with the global average of 5%. One of them is Felista Mwingira, a parasitologist at the University of Dar es Salaam in Tanzania. She exemplifies how African early-career researchers have been forging ahead in their research careers in the absence of a formal structure of postdoc positions.

Mwingira obtained her PhD in 2014 from the University of Basel in Switzerland at the age of 33 — which she says is very young for researchers in Tanzania. By the time she started her studies, she was already permanently employed by her university in Tanzania, and was able to return to that post after finishing her PhD. Back home, she could take three months paid maternity leave for each of her two children, born four years apart. And although juggling pregnancies and bringing up children with the demands of an academic career was a challenge, it meant she had job security — something postdocs at the same stage in their lives in other parts of the world often lack.

Mwingira’s work after her PhD was not technically a postdoc. But as her children got older, she sought out a mentorship arrangement at her university that provides her with research training and, sometimes, extra money from the projects she works on. It’s not a formal postdoc, but she hopes it will help her to attain the publication ‘points’ required in the Tanzanian university system to progress up the academic career ladder — something that does not depend on more-senior positions becoming available. She hopes to be promoted in the near future, but says she would also like to embark on a full-time postdoc position to “sharpen my scientific skills”.

So far, Mwingira considers herself lucky. Her children are now four and eight, and while she says that her life as an early-career academic still has ups and downs, she is thankful for the stability she has enjoyed so far in her career. “I think that I’m better off compared to postdocs in high-income countries.”

That feeling of being better off than people elsewhere certainly does not translate to sub-Saharan Africa’s most prominent research nation: South Africa. There, postdoc numbers have been rising for a couple of decades, growing from around 300 in 1999 to nearly 3,000 in 2019 (ref. 1), and national surveys reveal postdoc frustrations that mirror those raised globally, with some country-specific gripes to boot.

Heidi Prozesky is a research scholar at the Centre for Research on Evaluation, Science and Technology at Stellenbosch University. She is one of the people behind South Africa’s first PhD tracer study, published in its final form in July 2023, which tracked the whereabouts of nearly 6,500 PhDs who had graduated in the country between 2010 and 2019. That survey found that around 20% had accepted at least one postdoctoral fellowship, either at home or abroad, on completing their PhDs, with a steady growth seen over the two decades. The postdocs spent a median of three years in the position, although one-quarter reported spending more than four years. One-third reported having accepted more than one postdoc — often, they said, because other work was not available.

A common refrain in the South African survey, which echoes the findings of Nature’s global surveys, is that postdocs feel like they are in limbo: neither students nor staff. In reality, postdocs in South Africa are technically students. This saves them from paying tax on their income, which are stipends, not salaries. But this designation also breeds resentment, because it means postdocs are treated like students: they can’t apply for grants and typically have no funding to travel to conferences or attend workshops.

In addition to the lack of opportunities, postdoc pay in South Africa is low compared with living costs. Last year, the National Research Foundation’s non-taxable postdoc stipends started at 200,000 rand (US$10,700). Female postdocs are allowed up to four months paid maternity leave. However, basic private medical insurance does not come as standard, meaning that postdocs have to pay for it out of their stipends if they want to avoid state health care, which many people in South Africa view as woefully inadequate. The stories of some postdocs “would make you cry”, says Palesa Mothapo, who heads research support and management at Nelson Mandela University in Port Elizabeth, South Africa. “These people have PhDs. And they end up going hungry.”

Growing pains

South Africa’s predicament stems partly from bottlenecks in the academic careers system. The number of people with a PhD graduating annually more than tripled between 2000 and 2018, increasing the demand for postdoctoral work. Postdoc positions have also increased, but further up the career ladder, the number of roles has been static. A study published this year1 in the South African Journal of Science found that the number of postdoc positions grew ten times faster between 2007 and 2019 in the country than did the growth in entry-level permanent jobs in academia.

Portrait of Palesa Mothapo looking at ants in an Eppendorf tube

Palesa Mothapo at Nelson Mandela University in Port Elizabeth, South Africa, says there needs to be more discussion around transferable skills for African postdocs.Credit: Stefan Els

But many also view South Africa’s postdoc malaise as a consequence of incentive structures in the country that place a premium on research publications. Postdocs have become cheap, low-commitment hires for universities that want to boost their output of research publications, which in South Africa earn the host institutions or departments cash subsidies from the government. Postdocs often have publication targets written into their appointments, Mothapo says. “But those papers don’t translate to money for the postdoc. It goes to the institution, to the host.”

There is some cause for cheer. Last December, the National Research Foundation announced it would raise its minimum annual postdoc stipend to 320,000 rand per year for new fellowships from 2024. But simply increasing postdoc stipends is unlikely to create more academic positions for postdocs who are looking for more job security. And the bottleneck seems to be worse for some groups. According to Prozesky, South Africa attracts a lot of postdocs from the rest of the African continent. Most come with the expectation that it will lead to a permanent job. The PhD tracer study found that many people from the rest of Africa end up disillusioned and feeling discriminated against. They struggle to move on from the postdoc status, and can face long delays in visa approvals when moving between posts. “They call it academic xenophobia,” says Prozesky.

Charles Teta, a Zimbabwean environmental chemist who did two postdocs in South Africa after a PhD in his home country, says that he noticed that South African citizens were less likely to take the postdoc route than were immigrants like him. “South Africans are more likely to get lectureship posts,” without having any postdoc experience, he says. In addition, a growing number of funding streams are not open to non-citizens — even those who are permanent residents. Eventually, those restrictions cause people to leave, he says.

Teta left South Africa last year to cover the maternity leave of an environmental-science lecturer at Queen Mary University of London. There, he enjoys the opportunity to teach — something he wasn’t expected to do during his postdocs. It’s been a happy choice so far, and he hopes to find another, similar position when his current one ends. He doesn’t miss the research treadmill, which, he says, “did not translate to mental and financial well-being”.

A call for creativity

Mothapo says that the rigid focus on research in South African postdoc roles is part of their problem. “The universities are not creative,” she says. Because postdocs are limited in how they can teach, and can’t apply for their own funding, she notes, they are missing out on learning skills that are beneficial for staying in academia, and that could open up alternative career paths in industry.

More-creative programmes have been trialled across the continent. Since 2019, the US National Institutes of Health (NIH), the Bill & Melinda Gates Foundation in Seattle, Washington and the African Academy of Sciences have been running the African Postdoctoral Training Initiative (APTI). The programme combines a two-year postdoc at a NIH institute in the United States with a two-year research grant that fellows can take back home to build their own research programmes. Notably, it is open only to researchers who have permanent positions already.

Daniel Amoako-Sakyi, an immunologist at the University of Cape Coast, Ghana, embarked on an APTI fellowship in late 2023. He is a postdoc in mid-life, and the fellowship has proved to be a good fit. He is a few months into his position at the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, where he will spend the next two years looking at biological reasons for the variance in efficacy seen in new malaria vaccines. His 15-year-old daughter has enrolled in a US high school, and his spouse, a fellow academic, aims to split her time between the United States and Nigeria.

In Bethesda, Amoako-Sakyi has none of the resource constraints that limit him in Ghana. Antibodies that would take months to ship to his home country arrive on his doorstep overnight. He expects the opportunity will supercharge his career, and hopes he’ll be able to take on some postdocs of his own when he returns home. He doesn’t expect it will be difficult to find them. “I think most researchers are looking for the right environment to flourish,” he says.

What comes next?

There are few certainties about the future of African postdocs. Those who spoke to Nature hope that their postdoc training will accelerate their careers — by helping them to win grants, get promotions and expand their research networks. In Uganda, Kabukye hopes to have organized funding and collaborators by the end of his postdoc so that he can carry on his research designing and implementing digital-health tools in resource-constrained settings. “Ideally, I would have positions at the UCI and at another university, to foster collaboration and exchange,” he says.

Portrait of Johnblack Kabukye

Physician Johnblack Kabukye from Uganda is doing a postdoc building electronic health tools at Stockholm University in Sweden.Credit: Johnblack Kabukye

However, with most of the continent’s research funding still coming from sources outside Africa — with the exception of a handful of countries, such as South Africa and Egypt — it’s likely that foreign funding will keep driving the creation of postdoc opportunities. And that can mean the positions aren’t always tailored to local needs.

Mothapo says that she often hears research funders talk about the need to create more postdoc positions. However, there is not enough discussion around the particular needs that African postdocs will have, especially the transferable skills that they will need if they want to transition to sectors such as industry. “I’m worried about their destinations,” she says.

Mwingira echoes her concern. She thinks that more formalized postdocs in Tanzania could lead to bottlenecks in the training system, as has been seen in South Africa and elsewhere. “Those problems will arise in Tanzania, too, but worse, because of the low salaries,” she says.

But Amoako-Sakyi does not think that the creation of more African postdocs has to result in frustration as they compete for rare academic posts. Many might already be employed by universities at that point in their careers. A postdoc could allow them to win grants from funders so that they can set up their own research groups and create opportunities for the next generation. He also thinks that the biotechnology industry in countries such as Ghana will grow, further increasing the demand for researchers in the country.

Nor does Amoako-Sakyi think that African postdocs need to end up in the same negative landscape that postdocs occupy elsewhere in the world. Such fears are not unfounded, he says, because concepts are often brought to the continent and adopted without thinking about the local context. But as his own fellowship shows, there are ways to tailor postdocs to African settings. “We should be very intentional about how we do it and try to correct old mistakes.”

[ad_2]

Source Article Link

Categories
Featured

This is what a single 256GB DDR5 memory module looks like — but you won’t be able to fit this Micron RAM in your desktop or laptop and it will almost certainly cost more than $10,000 if you can buy it

[ad_1]

Micron has showcased its colossal 256GB DDR5-8800 MCRDIMM memory modules at the recent Nvidia GTC 2024 conference.

The high-capacity, double-height, 20-watt modules are tailored for next-generation AI servers, such as those based on Intel‘s Xeon Scalable ‘Granite Rapid’ processors which require substantial memory for training.

[ad_2]

Source Article Link

Categories
Featured

Nvidia’s fastest AI chip ever could cost a rather reasonable $40,000 — but chances that you will actually be able to buy one on its own are very, very low and for a good reason

[ad_1]

In a recent interview with CNBC’s Jim Cramer, Nvidia CEO Jensen Huang shared details about the company’s upcoming Blackwell chip which cost $10 billion in research and development to create.

The new GPU, which is built on a custom 4NP TSMC process and packs a total of 208 billion transistors (104 billion per die), with 192GB of HMB3e memory and 8TB/s of memory bandwidth, involved the creation of new technology because what the company was trying to achieve “went beyond the limits of physics,” Huang said.



[ad_2]

Source Article Link

Categories
Featured

This is what Nvidia’s Exaflop supercomputer-in-a-rack looks like — the DGX GB200 NVL72 tower most likely uses 48V, 2.5kA to deliver a staggering 1,440 petaflops, could cost millions

[ad_1]

Nvidia recently unveiled its DGX GB200 NVL72 supercomputer-in-a-rack at Nvidia GTC 2024 and Patrick Kennedy at Serve The Home took a selection of great photos showcasing the impressive beast.

The name of the DGX GB200 NVL72 tells you much of what you need to know. The GB200 signifies the Grace Blackwell GB200 compute structure, while the NVL72 denotes there are 72 Blackwell GPUs connected by NVLink.

The Blackwell platform contains 208 billion transistors across its two GPU dies. These are connected by 10 TB/second chip-to-chip link into a single, unified GPU. Blackwell, set to ship later this year, will reportedly offer up to 20 petaflops of FP4 power and be up to 30x faster than Hopper for AI inference tasks.

Nvidia GTC 2024

TechRadar Pro also snapped our own picture of the DGX GB200 at Nvidia GTC 2024 (Image credit: Future / Mike Moore)

120kW power load

[ad_2]

Source Article Link

Categories
Life Style

Cutting-edge CAR-T cancer therapy is now made in India — at one-tenth the cost

[ad_1]

Coloured scanning electron micrograph (SEM) of T lymphocyte cells (pink) attached to a cancer cell.

T cells (pink) attack a cancer cell (yellow) in this scanning electron micrograph image.Credit: Steve Gschmeissner/SPL

A small Indian biotechnology company is producing a home-grown version of a cutting-edge cancer treatment known as chimeric antigen receptor (CAR) T-cell therapy that was pioneered in the United States. CAR-T therapies are used mainly to treat blood cancers and have burgeoned in the past few years. The Indian CAR-T therapy costs one-tenth that of comparable commercial products available globally.

A single treatment of NexCAR19, manufactured by Mumbai-based ImmunoACT, costs between US$30,000 and $40,000. The first CAR-T therapy was approved in the United States in 2017, and commercial CAR-T therapies currently cost between $370,000 and $530,000, not including hospital fees and drugs to treat side effects. These treatments have also shown promise in treating autoimmune diseases and brain cancer.

India’s drug regulator approved NexCAR19 for therapeutic use in India in October. By December, ImmunoACT was administering the therapy to paying patients, and it is now treating some two-dozen people a month in hospitals across the country.

“It’s a dream come true,” says Alka Dwivedi, an immunologist who helped to develop NexCAR19 and is now at the US National Cancer Institute (NCI) in Bethesda, Maryland. Her voice becomes tender as she describes seeing the first patient’s cancer go into remission. These are people for whom all other treatments have failed, says Dwivedi. “They are getting cured.”

“It’s very positive news,” says Renato Cunha, a haematologist at the Grupo Oncoclínicas in São Paulo, Brazil. He says the Indian product could pave the way for making advanced cellular therapies accessible to other low- and middle-income countries. “Hope is the word that comes to mind.”

The product is also a reality check for researchers in high-income countries, says Terry Fry, an immunologist and paediatric oncologist at the University of Colorado Anschutz Medical Campus in Denver, who has advised the researchers involved in setting up ImmunoACT. “It lights a little fire under all of us to look at the cost of making CAR-T cells, even in places like the United States.”

Tremendous need

CAR-T therapy involves taking someone’s blood and isolating immune components known as T cells. These are genetically modified in the laboratory to express a receptor, known as a CAR, on their surface. This helps the immune cells to find and kill cancer cells. The engineered cells are then mass-produced and infused back into the patient, in whom they proliferate and get to work.

Data on demand for these therapies in India are limited, but one study looking at a specific form of leukaemia found that up to 15 people in 100,000 are diagnosed with the disease, half of whom relapse within two years of receiving treatment, such as chemotherapy, and who subsequently choose palliative care1. There is a “tremendous patient need”, says Nirali Shah, a paediatric oncologist at the NCI, who is also an academic collaborator of the researchers at ImmunoACT.

NexCAR19 is similar to its US counterparts, yet distinct in key ways. Like four of the six CAR-T therapies approved by the US Food and Drug Administration (FDA), it is designed to target CD19, a marker found on B-cell cancers2. However, in existing commercial therapies, the antibody fragment at the end of a CAR is typically from mice, which limits its durability because the immune system recognizes it as foreign and eventually eliminates it. Therefore, in NexCAR19, Dwivedi and her colleagues added human proteins to the mouse antibody tips.

Lab studies showed that the ‘humanized’ CAR had comparable antitumour activity to a mouse-derived one and induced the production of lower levels of proteins called cytokines2. This is important, because some people with cancer who receive CAR-T therapy experience an extreme inflammatory reaction known as cytokine-release syndrome, which can be life-threatening.

Trial data

Early-stage clinical trials for NexCAR19 in adults with different forms of lymphoma and leukaemia, showed that in 19 of the 33 people who received the therapy, the tumours had completely disappeared at the one-month follow-up3. The tumours in another four people had shrunk by half — achieving an overall response rate of 70%. Trial participants will be followed for at least five years.

“Whether this will hold or not is something only time will tell,” says Hasmukh Jain, a medical oncologist at Tata Memorial Centre in Mumbai, who led the trials.

Natasha Kekre, a haematologist at the Ottawa Hospital, points out that the results are based on a small number of participants with a range of blood cancers, which makes it difficult to assess the treatment’s efficacy for specific cancers.

Only two of the participants experienced more severe forms of cytokine-release syndrome, and none had neurotoxicities, another common but temporary side effect of CAR-T therapy.

The safety profile is better than that of some of the FDA-approved CAR-T treatments, says Kekre. This could be related to the product, as well as to years of the scientific and medical community learning how to better care for patients, she says.

Humanizing the CAR probably contributed to the therapy’s positive safety profile, says Rahul Purwar, an immunologist at the Indian Institute of Technology Bombay, and founder of ImmunoACT. But others say that link has yet to be established.

Fry says the setting and type of patient treated in India could also affect the results. “The toxicity profile of CAR-T cells is driven by a lot of other patient factors.”

A technician at work in the ImmunoACT cGMP Facility for NexCAR19 Production.

A member of the ImmunoACT team preparing the NexCAR19 cancer treatment.Credit: ImmunoACT

Slashing costs

Although the treatment’s price tag is still high for many Indians, whose annual gross national income per capita is less than $2,500, NexCAR19’s cost offers hope that CAR-T therapy can be made more cheaply in other countries and contexts. To slash costs, the team developed, tested and manufactured the product entirely in India, where labour is cheaper than in high-income countries.

To introduce CARs to T cells, researchers typically use lentiviruses, which are expensive. Purchasing enough lentiviral vector for a trial of 50 people can cost up to US$800,000 in the United States, says Steven Highfill, an immunologist at the US National Institutes of Health Clinical Center in Bethesda, who has advised the Indian team. Scientists at ImmunoACT make this gene-delivery vehicle themselves.

The Indian team also found a cheaper way to mass-produce the engineered cells, avoiding the need for expensive automated machinery, says Highfill.

Patients’ costs are further reduced by the therapy’s improved safety profile compared with some of the other FDA-approved products, Purwar says. This meant that most patients did not need to spend time in intensive-care units.

Purwar hopes to further cut costs, including by scaling up production. ImmunoACT is planning to export the therapy to Mexico, and to develop new products, including a treatment for another form of blood cancer known as multiple myeloma.

But ImmunoACT faces competition. Several other Indian companies have launched local CAR-T trials, including Immuneel Therapeutics in Bengaluru, which has licensed technology developed by Spanish academics.

[ad_2]

Source Article Link

Categories
Featured

The Asus ROG NUC carries the torch for Intel’s mini gaming PC dreams, but the cost of entry is still too steep

[ad_1]

Asus first revealed the Asus ROG NUC back at CES 2024, and now more information on the pricing and a release date is coming out regarding the small form factor gaming PC, which could easily be one of the best gaming PCs in the market.

Thanks to a pre-order listing at European retailer Proshop, and reported on by PC Gamer, we now know that the mini-gaming PC will run you €2,500, which translates to about $2,700 for the high-end configuration, though it likely won’t cost that much in the US. That version includes an Intel Core Ultra 9 185H CPU and RTX 4070 GPU, as well as 2x16GB of DDR5 memory and 1TB SSD of storage. According to that same listing, it’s set for an April 10, 2024 release.

[ad_2]

Source Article Link